Skip to main content
Nature Portfolio logoLink to Nature Portfolio
. 2022 Aug 5;3(9):1138. doi: 10.1038/s43018-022-00430-w

Author Correction: Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer

Laura M Spring 1,#, Hyo Han 2,#, Minetta C Liu 3, Erika Hamilton 4, Hanna Irie 5, Cesar A Santa-Maria 6, James Reeves 7, Peng Pan 8,10, Ming Shan 8,11, Yongqiang Tang 8, Julie R Graham 8,12, Sebastien Hazard 8,13, Leif W Ellisen 1,9, Steven J Isakoff 1,
PMCID: PMC9499859  PMID: 35931884

Correction to: Nature Cancer 10.1038/s43018-022-00400-2, published online 4 July 2022.

In the version of this article initially published, in the first sentence of the second paragraph now reading “Niraparib is a PARP-1/2 inhibitor approved for recurrent or advanced ovarian cancers,” the word “endometrial” originally appeared in place of “ovarian”. The error has been corrected in the HTML and PDF versions of the article.


Articles from Nature Cancer are provided here courtesy of Nature Publishing Group

RESOURCES